Felicitas Thol

发表

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Michael Heuser, Katharina Wagner, Brigitte Schlegelberger, 2010, Blood.

Precision oncology for acute myeloid leukemia using a knowledge bank approach

Inigo Martincorena, Verena I Gaidzik, Peter J Campbell, 2017, Nature Genetics.

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

Ulrich Lehmann, Ute Modlich, Michael Heuser, 2013, Blood.

Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.

Franco Locatelli, Michael Heuser, Seishi Ogawa, 2012, Blood.

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation

Verena I Gaidzik, Michael Heuser, Lars Bullinger, 2019, Nature Communications.

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.

Michael Heuser, Brigitte Schlegelberger, Arnold Ganser, 2012, Blood.

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis

Michael Heuser, Katharina Wagner, Brigitte Schlegelberger, 2010, Haematologica.

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Benjamin L. Ebert, Michael R. Savona, John M. Bennett, 2019, Nature Medicine.

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

Michael Heuser, Daniela Weber, Hartmut Döhner, 2015, British journal of haematology.

Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group.

Verena I Gaidzik, Thomas Schroeder, Thomas Kindler, 2019, Blood.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Michael Stadler, Verena I Gaidzik, Michael Heuser, 2018, Blood.